Close Menu

NEW YORK (GenomeWeb) – Every new study that is published about CRISPR-Cas-based genome editing seems to add yet another possible use to the growing list of what could be done with the technology: therapeutics for a variety of diseases, administered both in vivo and ex vivo; gene drives to control the spread of disease; agricultural applications to increase crop yields and create healthier animals, and so on.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.